These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 15927837)

  • 1. An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent.
    Banerjee S; Das T; Chakraborty S; Samuel G; Korde A; Venkatesh M; Pillai MR
    Bioorg Med Chem; 2005 Jul; 13(13):4315-22. PubMed ID: 15927837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy.
    Banerjee S; Das T; Chakraborty S; Samuel G; Korde A; Srivastava S; Venkatesh M; Pillai MR
    Nucl Med Biol; 2004 Aug; 31(6):753-9. PubMed ID: 15246366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
    Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
    Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel 99mTc-labeled testosterone derivative as a potential agent for targeting androgen receptors.
    Das T; Banerjee S; Samuel G; Bapat K; Subramanian S; Pillai MR; Venkatesh M
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5788-92. PubMed ID: 16949820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
    Michel RB; Andrews PM; Rosario AV; Goldenberg DM; Mattes MJ
    Nucl Med Biol; 2005 Apr; 32(3):269-78. PubMed ID: 15820762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor.
    Das T; Chakraborty S; Banerjee S; Venkatesh M
    Appl Radiat Isot; 2007 Mar; 65(3):301-8. PubMed ID: 17110119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
    Das T; Chakraborty S; Banerjee S; Mukherjee A; Samuel G; Sarma HD; Nair CK; Kagiya VT; Venkatesh M
    Bioorg Med Chem; 2004 Dec; 12(23):6077-84. PubMed ID: 15519153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production logistics of 177Lu for radionuclide therapy.
    Pillai MR; Chakraborty S; Das T; Venkatesh M; Ramamoorthy N
    Appl Radiat Isot; 2003; 59(2-3):109-18. PubMed ID: 12941498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on efficacy of a novel 177Lu-labeled porphyrin derivative in regression of tumors in mouse model.
    Sarma HD; Das T; Banerjee S; Venkatesh M; Vidyasagar PB; Mishra KP
    Curr Radiopharm; 2011 Apr; 4(2):150-60. PubMed ID: 22191655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
    van Essen M; Krenning EP; Kooij PP; Bakker WH; Feelders RA; de Herder WW; Wolbers JG; Kwekkeboom DJ
    J Nucl Med; 2006 Oct; 47(10):1599-606. PubMed ID: 17015894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
    Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
    Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
    Fortin MA; Orlova A; Malmström PU; Tolmachev V
    Int J Mol Med; 2007 Feb; 19(2):285-91. PubMed ID: 17203203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma.
    Sundberg AL; Gedda L; Orlova A; Bruskin A; Blomquist E; Carlsson J; Tolmachev V
    Cancer Biother Radiopharm; 2004 Apr; 19(2):195-204. PubMed ID: 15186600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
    Das T; Chakraborty S; Unni PR; Banerjee S; Samuel G; Sarma HD; Venkatesh M; Pillai MR
    Appl Radiat Isot; 2002 Aug; 57(2):177-84. PubMed ID: 12150276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
    Miao Y; Fisher DR; Quinn TP
    Nucl Med Biol; 2006 Aug; 33(6):723-33. PubMed ID: 16934691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions.
    Zhernosekov KP; Perego RC; Dvorakova Z; Henkelmann R; Türler A
    Appl Radiat Isot; 2008 Sep; 66(9):1218-20. PubMed ID: 18359234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels.
    Nasir A; Gardner NM; Strosberg J; Ahmad N; Choi J; Malafa MP; Coppola D; Kwekkeboom DJ; Teunissen JJ; Kvols LK
    Pancreas; 2008 Apr; 36(3):309-13. PubMed ID: 18362846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
    Rasaneh S; Rajabi H; Babaei MH; Daha FJ; Salouti M
    Nucl Med Biol; 2009 May; 36(4):363-9. PubMed ID: 19423003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 177Lu-DOTA-porphyrin conjugate: a potential agent for targeted tumor radiotherapy detection.
    Bhadwal M; Mittal S; Das T; Sarma HD; Chakraborty S; Banerjee S; Pillai MR
    Q J Nucl Med Mol Imaging; 2014 Jun; 58(2):224-33. PubMed ID: 24231798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
    Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
    Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.